EyePoint, Inc. Common Stock EYPT

EyePoint Pharmaceuticals, Inc. es una empresa biofarmacéutica en fase clínica. La empresa se enfoca en el desarrollo y comercialización de productos oftálmicos para el tratamiento de enfermedades oculares. La cartera de la empresa aprovecha su tecnología Durasert (Durasert) para la entrega sostenida de medicamentos intraoculares, incluida la entrega de EYP-1901, un tratamiento de entrega sostenida en investigación para enfermedades retinianas mediadas por el factor de crecimiento endotelial vascular (anti-VEGF). Sus programas adicionales en cartera incluyen EYP-2301, un agonista prometedor de TIE-2, razuprotafib, formulado en Durasert E para potencialmente mejorar los resultados en enfermedades retinianas graves. EYP-1901 se encuentra actualmente en ensayos clínicos de Fase 2 como tratamiento de entrega sostenida para la degeneración macular asociada a la edad húmeda (AMD húmeda), la retinopatía diabética no proliferativa (RDNP) y el edema macular diabético (EMD). Los otros productos de la empresa incluyen YUTIQ y DEXYCU.

EYPT hizo una agrupación de acciones (split inverso) de 1:10 el 9 de diciembre de 2020: cada 10 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 8 sept

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

  Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.

  

• GlobeNewswire Inc. 4 sept

  EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm

  EyePoint Inc. (NASDAQ: EYPT) announced disappointing Phase 3 clinical trial results for DURAVYU on August 17, 2026, failing to meet its primary endpoint in the LUGANO trial for wet age-related macular degeneration treatment. The stock subsequently dropped over 66%, prompting a securities litigation investigation by KTMC on behalf of affected investors.

  

• GlobeNewswire Inc. 2 sept

  EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

  EyePoint, Inc. (EYPT) announced its participation in three major investor conferences in September 2026, including Citi Biopharma, Cantor Global Healthcare, and Morgan Stanley Global Healthcare conferences. The company will also present multiple scientific presentations at The Retina Society's 59th Annual Scientific Meeting, focusing on its lead product candidate DURAVYU (vorolanib intravitreal insert) for retinal diseases, including Phase 3 trial data for wet AMD treatment.

  

• GlobeNewswire Inc. 16 jun

  EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  EyePoint, Inc. granted non-statutory stock options to three new employees as inducement awards on June 15, 2026. The company granted options to purchase 39,700 shares at an exercise price of $12.08 per share with a ten-year term and four-year vesting schedule. The grants were approved by the Compensation Committee in accordance with NASDAQ regulations.